StockNews.com Initiates Coverage on BioLineRx (NASDAQ:BLRX)

Equities researchers at StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price target on BioLineRx from $840.00 to $360.00 and set a “buy” rating on the stock in a research note on Monday, November 25th.

BioLineRx Trading Down 4.8 %

Shares of BLRX stock opened at $3.39 on Tuesday. The firm has a fifty day moving average of $7.57 and a 200-day moving average of $17.86. The stock has a market cap of $6.78 million, a price-to-earnings ratio of -0.39 and a beta of 1.41. BioLineRx has a 52-week low of $3.24 and a 52-week high of $57.60. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($2.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.20) by $0.40. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. On average, equities research analysts forecast that BioLineRx will post -5.8 earnings per share for the current fiscal year.

Institutional Trading of BioLineRx

An institutional investor recently raised its position in BioLineRx stock. Atria Investments Inc increased its holdings in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,974 shares of the biotechnology company’s stock after acquiring an additional 29,193 shares during the period. Atria Investments Inc owned about 0.17% of BioLineRx worth $72,000 at the end of the most recent quarter. Institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.